{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-133331","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.604929+00:00","generated_at":"2026-05-15T08:14:11.465574+00:00","sec_items":["1.03","2.04","5.02","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"confidence":"high","headline":"IO Biotech files Chapter 7 bankruptcy, ceases operations, all directors and employees terminated","bullets":["Filed Chapter 7 bankruptcy petition in Delaware on March 31, 2026; company ceases operations.","Chapter 7 trustee to liquidate assets; it is unlikely common stockholders will receive any payment.","All board members (Peter Hirth, Helen Collins, etc.) resigned; CEO Mai-Britt Zocca and CFO Amy Sullivan terminated.","Default triggered on €22.5 million EIB loan; EIB may demand immediate repayment but stay under bankruptcy.","Audit of 2025 financials not completed; company will not file 10-K or any periodic reports."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-133331","json":"https://secwatch.observer/filing/0001193125-26-133331.json","markdown":"https://secwatch.observer/filing/0001193125-26-133331.md","text":"https://secwatch.observer/filing/0001193125-26-133331.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312526133331/0001193125-26-133331-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312526133331/d87973d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:14:11.465574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}